Skip to main content

Table 3 Overall adverse events (N = 385)

From: Erlotinib treatment after platinum-based therapy in elderly patients with non-small-cell lung cancer in routine clinical practice – results from the ElderTac study

 

Patients, n (%)

Patients with ≥1 AE

296 (76.9)

Patients with ≥1 AE CTC grade ≥ 3

105 (27.3)

Patients with ≥1 SAE

112 (29.1)

Treatment discontinuations due to AE

107 (27.8)

Most common AEs (frequency ≥ 5%)

 Rash

174 (45.2)

 Diarrhea

87 (22.6)

 Dyspnea

66 (17.1)

 Fatigue

65 (16.9)

 Cough

44 (11.4)

 Malignant neoplasm progression

31 (8.1)

 Decreased appetite

28 (7.3)

 Nausea

24 (6.2)

 General physical health deterioration

21 (5.5)

Affected system organ class

 Skin

194 (50.4)

 Respiratory system

107 (27.8)

 Gastrointestinal system

105 (27.3)

 General disorders

99 (25.7)

 Infections and infestations

44 (11.4)

 Neoplasms

40 (10.4)

 Metabolic system

35 (9.1)

  1. AE adverse event, CTC common toxicity criteria, SAE serious adverse event